Keep on strong watch for continuation in KOOL in the coming days, todays advance was muted by other headline stock movements and strong volume in NDX and DJI.
PRESS SOURCE MARKETWATCH
Cesca Therapeutics Inc surged 11% in premarket trade Monday, after the provider of automated cell processing and point-of-care, autologous cell-based therapies said its wholly-owned unit ThermoGenesis Corp. has acquired assets from privately held SynGen Inc. Thermogenesis has acquired most of SynGen's assets, including cell processing platform technology, for 20% of its stock, plus $1 million in a one-time cash payment, in a deal that closed on July 7. Philip Coelho, co-founder and chief technology officer of SynGen, has become CTO of ThermoGenesis with immediate effect. Cesca has placed the assets of its blood and bone-marrow processing device business with ThermoGenesis, which will now operate its device business. "The continued evolution of personalized medicine, especially promising new oncology treatments such as CAR-T therapies, demand that target cell populations be harvested with increasing speed, purity and efficiency," Coelho said in a statement. Cesca shares are down 6.7% in 2017 through Friday, while the S&P 500 SPX, +0.47% has gained 8%.
COMPANY PROFILE
Cesca Therapeutics, Inc. engages in the research, development, commercialization and marketing of automated technologies for cell-based therapies for use in regenerative medicine. It operates through the following segments: Device and Clinical Development. The Device segment includes development and commercialization of automated systems that provide good manufacturing practice, clinical grade cell-banking, cell-processing and cell-based therapeutics. The Clinical Development segment develops autologous stem cell-based therapeutics that address significant unmet medical needs for the vascular, cardiology, and orthopedic markets. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
PRESS SOURCE MARKETWATCH
Cesca Therapeutics Inc surged 11% in premarket trade Monday, after the provider of automated cell processing and point-of-care, autologous cell-based therapies said its wholly-owned unit ThermoGenesis Corp. has acquired assets from privately held SynGen Inc. Thermogenesis has acquired most of SynGen's assets, including cell processing platform technology, for 20% of its stock, plus $1 million in a one-time cash payment, in a deal that closed on July 7. Philip Coelho, co-founder and chief technology officer of SynGen, has become CTO of ThermoGenesis with immediate effect. Cesca has placed the assets of its blood and bone-marrow processing device business with ThermoGenesis, which will now operate its device business. "The continued evolution of personalized medicine, especially promising new oncology treatments such as CAR-T therapies, demand that target cell populations be harvested with increasing speed, purity and efficiency," Coelho said in a statement. Cesca shares are down 6.7% in 2017 through Friday, while the S&P 500 SPX, +0.47% has gained 8%.
COMPANY PROFILE
Cesca Therapeutics, Inc. engages in the research, development, commercialization and marketing of automated technologies for cell-based therapies for use in regenerative medicine. It operates through the following segments: Device and Clinical Development. The Device segment includes development and commercialization of automated systems that provide good manufacturing practice, clinical grade cell-banking, cell-processing and cell-based therapeutics. The Clinical Development segment develops autologous stem cell-based therapeutics that address significant unmet medical needs for the vascular, cardiology, and orthopedic markets. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks